Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA

http://pdfs.journals.lww.com/oncology-times/2016/10250/Potential_Genetic_Biomarker_Found_for.7.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1477833656638;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzdVSccpjyZsZb6SyvftA6EC8ekCuQ21KXNMUz6c0lLzg+FeJrsim2+Lk68UsQpnRSt;hash|fiXUctPWjRYgywdf4d4yyg==

Vol. 2 Nr. 9 Página: 1236 - 8 Data da publicação: 01/09/2016 Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States For aggressive, localized prostate cancer, the combination of androgen deprivation therapy (ADT) with radiotherapy (RT) is one of the best-studied treatments. Multiple randomized clinical trials have consistently demonstrated that adding ADT to RT improves survival. 1-5 Despite this large amount of level 1 evidence, controversy remains regarding the role of ADT. There are concerns that ADT may not benefit (or may even harm) patients with comorbidities and that the survival ben- efit from ADT may be replaced by dose-escalated RT, even though the latter has never been shown to improve survival. Therefore, we examined the adoption of ADT vs dose- escalated RT across the United States. We analyzed data for patients with intermediate-risk (n =

In this phase II trial we evaluated ef fi cacy and safety of panitumumab in combination with gemcitabine and carboplatin as treatment for metastatic triple-negative breast cancer (TNBC). Seventy-one women were treated. The median progression-free survival was 4.4 months. The results of this trial do not support com- bination of panitumumab with gemcitabine and carboplatin in the treatment of patients with TNBC. Background: Triple-negative breast cancer (TNBC) is a subtype with poor prognosis, and treatment options are limited to chemotherapy. Because the epidermal growth factor receptor (EGFR) is overexpressed in up to 70% of these tumors, this phase II trial was designed to evaluate the ef fi cacy and safety of panitumumab in combination with gemcitabine and carboplatin as fi rst- or second-line treatment for metastatic TNBC. Patients and Methods: Adult women with metastatic TNBC with a maximum of 1 previous chemotherapy regimen were eligible. Patients receiv

Abstract Background Systemic chemotherapy is the mainstay of treatment for metastatic breast cancer with the role of surgery being strictly limited for palliation of metastatic complications or locoregional relapse. An increasing number of studies examining the role of therapeutic hepatic metastasectomy show encouraging survival results. A systematic review was undertaken to define its safety, efficacy and to identify prognostic factors associated with survival. Methods Electronic search of the MEDLINE and PubMed databases (January 2000–January 2011) to identify studies reporting outcomes of hepatectomy for breast cancer liver metastases (BCLM) with hepatectomy was undertaken. Two reviewers independently appraised each study using a predetermined protocol. Safety and clinical efficacy was synthesised through a narrative review with full tabulation of results of all included studies. Results Nineteen studies were examined. This comprised of 553 patients. Hepatectomy for BCL

http://www.sciencedirect.com/science/article/pii/S0748798312003046?np=y Resection of liver metastases in patients with breast cancer: Survival and prognostic factors G.A.M. van Walsum a , * , J.A.M. de Ridder b , C. Verhoef c , K. Bosscha d , T.M. van Gulik e , E.J. Hesselink f , T.J.M. Ruers g , M.P. van den Tol h , I.D. Nagtegaal i , M. Brouwers j , R. van Hillegersberg k , R.J. Porte l , A.M. Rijken m , L.J.A. Strobbe n , J.H.W de Wilt b on behalf of the Dutch Liver Surgeons Group Abstract Aims : Patients with breast cancer metastasized to the liver have a median survival of 4 e 33 months and treatment options are usually re- stricted to palliative systemic therapy. The aim of this observational study was to evaluate the effectiveness and safety of resection of liver metastases from breast cancer and to identify prognostic factors for overall survival. Methods : Patients were identified using the national reg